Your browser doesn't support javascript.
loading
SARS-CoV-2 Seroprevalence in Germany.
Gornyk, Daniela; Harries, Manuela; Glöckner, Stephan; Strengert, Monika; Kerrinnes, Tobias; Heise, Jana-Kristin; Maaß, Henrike; Ortmann, Julia; Kessel, Barbora; Kemmling, Yvonne; Lange, Berit; Krause, Gérard.
Afiliação
  • Gornyk D; Department of Epidemiology, Helmholtz Center for Infection Research, Braunschweig; RNA Biology of Bacterial Infections, Helmholtz Institute for RNA-Based Infection Research, Würzburg; TI Bioresources, Biodata, and Digital Health (TI BBD), German Center for Infection Research (DZIF), Braunschweig; TWINCORE, Center for Experimental and Clinical Infection Research, Hanover.
Dtsch Arztebl Int ; 118(48): 824-831, 2021 12 03.
Article em En | MEDLINE | ID: mdl-35191825
ABSTRACT

BACKGROUND:

Until now, information on the spread of SARS-CoV-2 infections in Germany has been based mainly on data from the public health offices. It may be assumed that these data do not include many cases of asymptomatic and mild infection.

METHODS:

We determined seroprevalence over the course of the pandemic in a sequential, multilocal seroprevalence study (MuSPAD). Study participants were recruited at random in seven administrative districts (Kreise) in Germany from July 2020 onward; each participant was tested at two different times 3-5 months apart. Test findings on blood samples were used to determine the missed-case rate of reported infections, the infection fatality rate (IFR), and the association between seropositivity and demographic, socio-economic, and health-related factors, as well as to evaluate the self-reported results of PCR and antigenic tests. The registration number of this study is DRKS00022335.

RESULTS:

Among non-vaccinated persons, the seroprevalence from July to December 2020 was 1.3-2.8% and rose between February and May 2021 to 4.1-13.1%. In July 2021, 35% of tested persons in Chemnitz were not vaccinated, and the seroprevalence among these persons was 32.4% (07/2021). The surveillance detection ratio (SDR), i.e., the ratio between the true number of infections estimated from seroprevalence and the actual number or reported infections, varied among the districts included in the study from 2.2 to 5.1 up to December 2020 and from 1.3 to 2.9 up to June 2021, and subsequently declined. The IFR was in the range of 0.8% to 2.4% in all regions except Magdeburg, where a value of 0.3% was calculated for November 2020. A lower educational level was associated with a higher seropositivity rate, smoking with a lower seropositivity rate. On average, 1 person was infected for every 8.5 persons in quarantine.

CONCLUSION:

Seroprevalence was low after the first wave of the pandemic but rose markedly during the second and third waves. The missed-case rate trended downward over the course of the pandemic.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Dtsch Arztebl Int Assunto da revista: MEDICINA / SAUDE PUBLICA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Dtsch Arztebl Int Assunto da revista: MEDICINA / SAUDE PUBLICA Ano de publicação: 2021 Tipo de documento: Article